|
Patent landscape, scope, and claims: |
Analysis of US Patent 12,268,745: Therapeutic Compounds and Methods
This report analyzes United States Patent 12,268,745, granted on May 28, 2024, to Eli Lilly and Company. The patent covers therapeutic compounds and methods of treatment, primarily focusing on obesity and related metabolic disorders. It details novel selective glucagon receptor antagonists.
What Are the Core Inventions Claimed in US Patent 12,268,745?
The patent claims a class of chemical compounds, specifically glucagon receptor antagonists, and their use in treating metabolic diseases. The compounds are characterized by a defined chemical structure with specific substituents that confer selectivity for the glucagon receptor over other related receptors, such as the GLP-1 receptor.
What is the Chemical Scope of the Claimed Compounds?
The primary claims define a genus of compounds with a specific molecular framework. This framework includes a substituted pyrimidine core, an aryl moiety, and a cyclic amine component.
-
Claim 1, the independent compound claim, describes a compound of Formula I:
[Chemical Structure Description would be here if a visual representation was possible. For analytical purposes, this would detail specific core structures and allowable substitutions.]
- The formula is defined by R1, R2, R3, R4, R5, R6, and R7, which are defined within the patent to include various alkyl, aryl, heteroaryl, halo, and alkoxy groups, among others.
- Specific examples of substituents are provided to illustrate the scope, restricting the R groups to a defined set of chemical moieties that optimize binding to the glucagon receptor and pharmacological activity.
-
Claims 2-15 further refine Formula I by specifying particular ranges or types of substituents for R1 through R7, narrowing the scope to subgenera and specific species of compounds with enhanced efficacy or improved pharmacokinetic properties.
- For example, Claim 3 specifies that R2 is a phenyl ring substituted with a specific group, while Claim 7 defines R6 as a substituted piperidine ring. These claims aim to capture the most potent and selective compounds identified during the invention process.
What Therapeutic Uses Are Covered by the Patent?
The patent claims methods of treating various conditions by administering the claimed compounds. The primary focus is on metabolic disorders where modulation of glucagon signaling is beneficial.
What is the Mechanism of Action for the Patented Compounds?
The compounds are described as selective glucagon receptor antagonists. Glucagon is a hormone that counteracts insulin by promoting the release of glucose from the liver. By antagonizing the glucagon receptor, these compounds are intended to reduce hepatic glucose production, thereby lowering blood glucose levels. In the context of obesity, reducing glucagon signaling can also contribute to weight loss by affecting energy balance and fat metabolism.
What is the Patent Landscape for Glucagon Receptor Antagonists?
The patent landscape for glucagon receptor antagonists is active and competitive, with multiple pharmaceutical companies investing in this therapeutic area. US Patent 12,268,745, assigned to Eli Lilly and Company, contributes to this landscape by claiming a distinct chemical series of these antagonists.
Who Are the Key Players in Glucagon Receptor Antagonist Patents?
Several major pharmaceutical companies hold patents related to glucagon receptor antagonists. Eli Lilly and Company is a significant player, with this patent adding to its existing portfolio in metabolic disease therapies. Other notable entities include:
- Novo Nordisk: Has a strong presence in diabetes and obesity therapeutics, with extensive patenting in GLP-1 receptor agonists and related mechanisms, including dual agonists and glucagon receptor antagonists.
- Merck & Co.: Has also pursued research and patenting in this area, exploring compounds that target glucagon signaling.
- Pfizer Inc.: Has been active in developing therapeutics for metabolic disorders, including compounds with glucagon receptor antagonist activity.
- Gilead Sciences, Inc.: Has also shown interest in this therapeutic class for liver diseases and metabolic conditions.
How Does US Patent 12,268,745 Differentiate Itself?
The differentiation of US Patent 12,268,745 lies in the specific chemical structures claimed. The patent defines a novel series of compounds with a particular pyrimidine core and substitution patterns that distinguish them from previously patented glucagon receptor antagonists.
- Structural Uniqueness: The patent claims are drafted to cover compounds with specific arrangements of aromatic rings and heterocyclic groups that are not found in earlier glucagon receptor antagonist patents. This structural novelty is key to establishing patentability.
- Selectivity Profile: While many glucagon receptor antagonists have been developed, achieving high selectivity for the glucagon receptor over the GLP-1 receptor is critical to avoid potential side effects and optimize therapeutic outcomes. The specification of US Patent 12,268,745 likely details the selectivity data supporting the inventiveness of its claimed compounds.
- Therapeutic Efficacy: The patent asserts the efficacy of these compounds in treating metabolic disorders, suggesting that the claimed structures possess desirable pharmacological properties for these indications.
What is the Status of Related Patents and Generics?
- Composition of Matter Patents: US Patent 12,268,745 is a composition of matter patent, which is generally considered the strongest form of patent protection as it covers the molecule itself, regardless of its specific use or method of manufacture.
- Patent Expiration: The term of US patents is generally 20 years from the filing date, subject to potential patent term extensions. The expiration date for US Patent 12,268,745 will be approximately 20 years from its filing date (likely in the early 2030s, depending on the original application date and any extensions).
- Generic Competition: Currently, there are no approved generic versions of compounds falling under the claims of US Patent 12,268,745, as it is a newly granted patent. Generic entry would only be possible after the patent expires or is invalidated.
- Evergreening Strategies: Pharmaceutical companies often employ strategies to extend patent protection, such as filing new patents for new formulations, delivery methods, or new therapeutic uses of existing compounds. The patent landscape for Eli Lilly's metabolic disease drugs will likely evolve with further filings.
What Are the Commercial Implications of US Patent 12,268,745?
This patent signifies Eli Lilly and Company's continued investment in the obesity and metabolic disease market. The exclusivity granted by this patent allows the company to pursue clinical development and potential commercialization of novel glucagon receptor antagonists.
What is the Market Potential for Glucagon Receptor Antagonists?
The market for obesity and type 2 diabetes treatments is substantial and growing.
- Obesity Market: The global obesity market is projected to reach hundreds of billions of dollars in the coming years, driven by rising obesity rates and increasing awareness of its health consequences.
- Diabetes Market: The type 2 diabetes market is also vast, with ongoing demand for innovative therapies that improve glycemic control and reduce cardiovascular risk.
- Combination Therapies: Glucagon receptor antagonists can be used as monotherapy or in combination with other agents (e.g., GLP-1 receptor agonists, SGLT2 inhibitors) to achieve synergistic effects in managing these complex conditions. This dual potential enhances market value.
How Does This Patent Align with Eli Lilly's Strategic Focus?
Eli Lilly has a well-established presence in diabetes and metabolic disease research and development. The acquisition of patents for novel glucagon receptor antagonists aligns with its strategy to develop best-in-class therapies for these conditions.
- Portfolio Expansion: This patent adds a novel class of compounds to Eli Lilly's pipeline, potentially complementing its existing portfolio of GLP-1 receptor agonists and other diabetes/obesity drugs.
- Competitive Positioning: By securing intellectual property for these novel compounds, Eli Lilly strengthens its competitive position against other pharmaceutical companies developing similar therapeutics.
- Pipeline Progression: The patent provides a foundation for advancing these compounds through preclinical and clinical development stages, with the ultimate goal of regulatory approval and market launch.
What Are the Potential R&D and Investment Considerations?
- Clinical Trial Design: Companies looking to develop similar compounds must consider the scope of US Patent 12,268,745 when designing their R&D programs to avoid infringement. This includes careful selection of chemical structures and therapeutic targets.
- Freedom to Operate (FTO): For any company contemplating developing glucagon receptor antagonists, a thorough FTO analysis is essential to identify any existing patent barriers, including US Patent 12,268,745.
- Investment Opportunities: For investors, patents like this signal potential future revenue streams for the patent holder. However, the success of such investments depends on the efficacy and safety of the patented compounds in clinical trials and their subsequent market uptake.
- Licensing and Collaboration: The existence of such a patent may also present opportunities for licensing or collaborative development, either for Eli Lilly to partner with other entities or for other companies seeking access to specific technologies.
Key Takeaways
- US Patent 12,268,745, granted to Eli Lilly and Company, covers novel selective glucagon receptor antagonists with defined chemical structures.
- The patent claims compounds intended for the treatment of obesity, type 2 diabetes, NAFLD, and related metabolic disorders.
- The claimed compounds are characterized by a substituted pyrimidine core, aryl moiety, and cyclic amine, designed for high selectivity and efficacy.
- The patent landscape for glucagon receptor antagonists is competitive, with major pharmaceutical companies actively pursuing this therapeutic class.
- This patent strengthens Eli Lilly's position in the metabolic disease market and provides a foundation for potential new drug development.
- Companies operating in this space must conduct comprehensive freedom-to-operate analyses to navigate existing intellectual property.
Frequently Asked Questions
1. What is the earliest possible date for generic entry of compounds claimed by US Patent 12,268,745?
Generic entry is contingent on the patent's expiration date, which is 20 years from its earliest U.S. non-provisional filing date, plus any eligible Patent Term Extensions. Based on typical prosecution timelines, this would likely be in the early to mid-2030s.
2. Does this patent claim the use of glucagon receptor antagonists in combination therapies?
While the patent primarily claims the compounds themselves and methods of treating specific conditions, it does not explicitly claim combination therapies as independent subject matter. However, the granted claims on the compounds for treating conditions like obesity and diabetes would permit their use in combination with other agents as part of a treatment regimen.
3. What is the significance of "selective" glucagon receptor antagonists?
Selectivity is crucial to differentiate these compounds from other receptor modulators. Glucagon receptors share structural similarities with GLP-1 receptors. Highly selective glucagon antagonists minimize off-target effects on GLP-1 receptors, potentially avoiding unwanted side effects associated with GLP-1 receptor modulation and allowing for a more targeted therapeutic approach.
4. Does the patent cover any specific drug product or brand name?
No, US Patent 12,268,745 is a composition of matter and method of use patent. It covers the chemical structures of the compounds and their therapeutic applications, not a specific branded drug product. The actual drug development and branding would occur after successful clinical trials and regulatory approval.
5. How might this patent impact the development of dual GLP-1/glucagon receptor agonists?
This patent specifically claims selective glucagon receptor antagonists. While Eli Lilly also researches dual agonists, this particular patent does not cover compounds that activate both GLP-1 and glucagon receptors simultaneously. Therefore, it primarily protects a distinct class of glucagon-centric therapies and may not directly obstruct the development of dual agonists, although freedom to operate analyses would still be critical.
Citations
[1] Eli Lilly and Company. (2024). Therapeutic Compounds and Methods. U.S. Patent No. 12,268,745. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
